Yoji Ishida

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacology +9

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 101 citations

Medicine, Hematology, Pharmacology +5

Epidemiological and clinical features of adult T‐cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey

Kisato Nosaka, Masako Iwanaga, Yoshitaka Imaizumi et al. · Cancer Science · 2017 · 77 citations · Full text

Medicine, Hematology, Oncology +17

Absence of pseudomembranes in<i>Clostridium difficile</i>-associated diarrhea in patients using immunosuppression agents

Ken‐ichi Nomura, Yoshiko Fujimoto, Mihoko Yamashita et al. · Scandinavian Journal of Gastroenterology · 2008 · 75 citations

Medicine, Infectious Diseases, Pathology +17